The FDA has approved Genentech’s TNKase (tenecteplase) for acute ischemic stroke, offering rapid, single-bolus treatment. Discover clinical insights and market trends in our latest article by Soumya Shashikumar at https://buff.ly/OlUGHfX. | Xtalks Webinars

Intravenous tenecteplase administered 4.5 to 24 hours after symptom onset improved the likelihood of excellent functional outcome at 90 days in patients with acute ischemic #stroke due to non–large vessel occlusion and salvageable brain tissue, compared with standard medical treatment. In this randomized clinical trial, 43.6% of patients receiving #tenecteplase achieved a modified Rankin Scale score of 0 or 1 vs 34.2% with standard care, but use of tenecteplase was associated with a higher incid

In ischemic stroke, tenecteplase may provide benefit when administered within 4.5 hours after the time the patient was last known to be well, but its safety and efficacy when administered at 4.5 to 24 hours are unclear. Research findings are summarized in this new Quick Take video. https://nej.md/3wa2tAR | The New England Journal of Medicine